SecBot SecBot
Insider Cluster (2 insiders) ·Filed Mar 11, 2026

ONCY

ONCOLYTICS BIOTECH INC
BULLISH
Impact 5/10
Horizonweeks Processed8mo ago
Insider cluster: 2 insiders, $15K total
Actionable Insight ▲ Bullish

While the dollar amount is small, the fact that both the CEO and a director are buying shares at current levels may indicate confidence ahead of potential catalysts. Traders should monitor for follow-on buying or upcoming clinical/data readouts.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.01
T+0 close · Mar 10, 2026 · via day close
Latest settled
−12.87%
T+60 · $0.8800
Vs SPY
−24.39%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 11 $1.01entry
  2. T+1 · 8mo ago −4.95%α −3.47% · $0.9600
  3. T+5 · 8mo ago −4.95%α −2.76% · $0.9600
  4. T+20 · 7mo ago +2.97%α +2.45% · $1.04
  5. T+60 · 6mo ago −12.87%α −24.39% · $0.8800
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Two corporate insiders at Oncolytics Biotech purchased shares in the open market within the past week, including CEO Kelly Jared and Director James T. Parsons, signaling confidence in the company. The total value of purchases was $15,148, a small but notable insider buying cluster.

Key Financial Metrics

Direction
buying
Total Value
$15.1K
Insiders
2

Key Facts

  • CEO Kelly Jared purchased 5,050 shares at $0.96 per share for a total of $4,848 in open-market transactions.
  • Director James T. Parsons purchased 10,000 shares at $1.03 per share for a total of $10,300 in open-market transactions.
  • All transactions were open-market purchases (P), indicating actual cash investment by insiders.
  • Total insider buying in the past 7 days: $15,148 across 2 transactions.

Financial Impact

$15,148 in total open-market purchases, representing approximately 0.015% of the company's $103M market cap.

insider ownershipmarket sentiment

Risk Factors

  • The total transaction value is low relative to market cap, limiting immediate market impact.
  • Biotech stocks like ONCY are highly sensitive to clinical trial outcomes and regulatory developments, which could override insider sentiment.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CONTEXT: Insider Cluster Data (2 trades, 7d window)cluster-ONCY-1773403240908

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 13, 2026